Google
Trusted Resources: News & Events
Latest announcements and gatherings
University of Illinois at Chicago awarded $4.6 million NIH grant for chronic pain research
The University of Illinois at Chicago has been awarded a $4.6 million grant from the National Heart, Lung, and Blood Institute to study the molecular neurobiology of chronic pain in patients with sickle cell disease and to develop potential new drug treatments.
While there have been many advances in managing the disease and acute pain crises, researchers still do not know much about how and why patients experience chronic pain.
The new funding will provide an opportunity for investigators to refine their tools and develop new therapeutic leads for treating chronic pain in sickle cell disease. They hope to identify various molecular mechanisms and explore ways to target one or more of these mechanisms for controlling pain in sickle cell disease.
+myBinderRelated Content
-
Sickle Cell Disease CoalitionThe Sickle Cell Disease Coalition (SCDC)...
-
Comparison of Adult and Adolescent Quality of Ambulatory and Emergency Care in Sickle Cell Disease: Ascq-Me and the ...Quality of care (QOC) has been anecdotal...
-
Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)GBT440 is First Potential Treatment for ...
-
Children’s Hospital of The King’s Daughters Sickle Cell ProgramChildren's Hospital of The King's Daught...
-
Carla JonesAnyone affected by sickle cell disease k...
-
Barriers and Facilitators to Care for Individuals With Sickle Cell Disease in Central North Carolina: The Emergency ...Background: Sickle cell disease (SCD) i...
-
Richard Lottenberg, MDDr. Richard Lottenberg is a faculty memb...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.